In line with our results, an independent report suggested NF1 alterations were potentially involved in ALK resistance [53] and a case report described a de novo NRASQ61K mutation upon development of ALK inhibitor resistance in a lorlatinib-treated neuroblastoma [54]. This evidence concerns the gene NF1 and neuroblastoma.